[Federal Register Volume 82, Number 172 (Thursday, September 7, 2017)]
[Notices]
[Page 42363]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-18992]



[[Page 42363]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--The National Institute for Innovation in 
Manufacturing Biopharmaceuticals

    Notice is hereby given that, on July 18, 2017, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), the University of Delaware, doing 
business as The National Institute for Innovation in Manufacturing 
Biopharmaceuticals (``NIIMBL''), has filed written notifications 
simultaneously with the Attorney General and the Federal Trade 
Commission disclosing (1) the identities of the parties to the venture 
and (2) the nature and objectives of the venture. The notifications 
were filed for the purpose of invoking the Act's provisions limiting 
the recovery of antitrust plaintiffs to actual damages under specified 
circumstances.
    Pursuant to Section 6(b) of the Act, the identities of the parties 
to the venture are: University of Delaware, Newark, DE; Purdue 
University, West Lafayette, IN; North Carolina State University, 
Raleigh, NC; Rensselaer Polytechnic Institute, Troy, NY; Johns Hopkins 
University, Baltimore, MD; Regents of University of Minnesota, 
Minneapolis, MN; National Institute for Pharmaceutical Technology and 
Education, Inc., Minneapolis, MN; University of Massachusetts, Lowell, 
MA; Southwest Research Institute, San Antonio, TX; Tulane University, 
New Orleans, LA; UNCW Research Foundation, or its assignee University 
of North Carolina at Wilmington, Wilmington, NC; Carnegie Mellon 
University, Pittsburgh, PA; East Carolina University, Greenville, NC; 
University of Georgia Research Foundation, Athens, GA; Texas A&M 
University System, College Station, TX; Clemson University, Clemson, 
SC; The Pennsylvania State University, University Park, PA; Georgia 
Tech Research Corporation, Atlanta, GA; Massachusetts Institute of 
Technology, Cambridge, MA; University of Maryland College Park, College 
Park, MD; Worcester Polytechnic Institute, Worcester, MA; Genentech, 
San Francisco, CA; Stratophase LP, Romsey, UNITED KINGDOM; Chromatan 
Corporation, State College, PA; ILC Dover LP, Frederica, DE; Sudhin 
Biopharma Co., Superior, CO; Artemis Biosystems, Inc., Cambridge, MA; 
Commissioning Agents, Indianapolis, IN; Unum Therapeutics, Inc., 
Cambridge, MA; RoosterBio, Inc., Avondale, PA; University of Maryland 
Baltimore, Baltimore, MD; Forsyth Technical Community College, Winston-
Salem, NC; University of Pennsylvania, Philadelphia, PA; Celgene 
Corporation, Summit, NJ; North Carolina Central University, Durham, NC; 
Massachusetts Life Sciences Center, Waltham, MA; North Carolina 
Biotechnology Center, Research Triangle Park, NC; Akron Biotechnology, 
LLC, Boca Raton, FL; and Accugenomics, Inc., Wilmington, NC. The 
general area of NIIMBL's planned activity is to engage in collaborative 
activities with the goals of: (a) Accelerating biopharmaceutical 
manufacturing innovation, (b) supporting the development of standards 
that enable more efficient and rapid manufacturing capabilities, and 
(c) educating and training a world-leading biopharmaceutical 
manufacturing workforce. Additional information about NIIMBL can be 
obtained from Dr. Kelvin Lee, Institute Director, NIIMBL, 15 Innovation 
Way, Newark, DE 19711, [email protected] and (302) 831-3716.

Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-18992 Filed 9-6-17; 8:45 am]
 BILLING CODE P